$758.33 Million in Sales Expected for West Pharmaceutical Services, Inc. (NYSE:WST) This Quarter

Wall Street brokerages expect that West Pharmaceutical Services, Inc. (NYSE:WSTGet Rating) will announce $758.33 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for West Pharmaceutical Services’ earnings, with estimates ranging from $751.70 million to $768.30 million. West Pharmaceutical Services reported sales of $723.60 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 4.8%. The business is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that West Pharmaceutical Services will report full year sales of $3.06 billion for the current fiscal year, with estimates ranging from $3.05 billion to $3.06 billion. For the next financial year, analysts forecast that the firm will post sales of $3.31 billion, with estimates ranging from $3.21 billion to $3.40 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WSTGet Rating) last released its quarterly earnings results on Thursday, April 28th. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.18 by $0.12. The business had revenue of $720.00 million during the quarter, compared to the consensus estimate of $720.92 million. West Pharmaceutical Services had a return on equity of 30.33% and a net margin of 23.76%. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 EPS.

Several analysts recently issued reports on WST shares. StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th. William Blair reiterated an “outperform” rating on shares of West Pharmaceutical Services in a research report on Tuesday, February 22nd.

WST opened at $296.26 on Wednesday. The business has a fifty day simple moving average of $374.85 and a 200 day simple moving average of $400.96. The company has a market capitalization of $21.95 billion, a PE ratio of 32.92, a price-to-earnings-growth ratio of 3.16 and a beta of 1.17. West Pharmaceutical Services has a 1 year low of $289.31 and a 1 year high of $475.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.89 and a quick ratio of 2.18.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 3rd. Stockholders of record on Wednesday, July 20th will be issued a dividend of $0.18 per share. The ex-dividend date is Tuesday, July 19th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.24%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 8.00%.

In other news, VP Quintin J. Lai sold 8,016 shares of the business’s stock in a transaction on Monday, March 14th. The stock was sold at an average price of $371.69, for a total transaction of $2,979,467.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.60% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in WST. Bell Investment Advisors Inc purchased a new stake in shares of West Pharmaceutical Services during the third quarter valued at approximately $25,000. Monolith Advisors purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $29,000. Allworth Financial LP increased its position in West Pharmaceutical Services by 140.0% in the first quarter. Allworth Financial LP now owns 72 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 42 shares during the last quarter. Addison Advisors LLC raised its stake in shares of West Pharmaceutical Services by 221.7% in the first quarter. Addison Advisors LLC now owns 74 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 51 shares during the period. Finally, Artemis Wealth Advisors LLC bought a new stake in shares of West Pharmaceutical Services in the first quarter valued at $35,000. Institutional investors own 93.25% of the company’s stock.

About West Pharmaceutical Services (Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

See Also

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.